第1个回答 2011-03-21
希望能帮助你
The name of an unbranched acyclic mono-or di-aldehyde is formed by goal: This article through the Chinese and foreign law contrast research, the related legal framework research, the hospital management system research and so on to make in the drugs re-evaluation related laws and regulations to be related the main body and the responsibility proposes the basis. Method: Went on the market the drugs re-evaluation present situation take our country as the foundation, plans to choose the re-evaluation possible responsibility main body to carry on feasibility studies and so on capacity, right ability, responsibility ability. Carries on the analysis according to the existing laws and regulations to the drugs re-evaluation responsibility main body's localization, judges its feasibility, or needs to consummate content. Takes the reference by the overseas drugs re-evaluation system to the responsibility main body's localization, according to "Pharmaceuticals administration" the request, embarks from our country's actual situation, proposed that the proper responsibility main body, the classification induces various responsibilities main body the right and the duty. Finally, went on the market the drugs re-evaluation responsibility main body to our country to put forward the proposal. Result and conclusion: Because went on the market the drugs re-evaluation is a systematic project, therefore links and so on drugs production, circulation, use, management by supervision involve after the production, the Operation of business, the Medical establishment, the Governmental agency and so on should shoulder drugs going on the market, re-evaluation work. May also establish the third party appraisal organization to participation completes went on the market the drugs re-evaluation work.
第2个回答 2011-03-11
Objective: this paper through comparative study and foreign law and relevant legal system research, hospital management system research, etc. For formulating drug regulations related to reassess its responsibilities related subject proposed basis. Methods: in our country has already listed drug again based evaluation actuality, plan to choose again evaluation may behave in the main responsibility of the ability, the rights of competence, responsibility ability feasibility study. According to the existing laws and regulations on drug evaluation responsibility subject localization again analysis, judge its feasibility, or need to consummate content. With foreign drugs again evaluation system for main responsibility orientation as reference, according to the requirements of the "drugadministration law, from the actual situation in our country, the paper points out the liability subject classification should be induces the main responsibility of rights and obligations. Finally, to our country already listed drug again evaluation responsibility subjects are proposed. Results and conclusion: because already listed drug again evaluation is a systematic project, so drug production, circulation, use, supervision and management involved production, trading enterprises and medical organizations, government agencies, etc. Are all should shoulder the drugs listed again after the evaluation work. Still can establish third-party evaluation institutions involved in complete already listed drug again evaluation.
双语对照查看
第3个回答 2011-03-12
Objective: this paper through comparative study and foreign law and relevant legal system research, hospital management system research, etc. For formulating drug regulations related to reassess its responsibilities related subject proposed basis. Methods: in our country has already listed drug again based evaluation actuality, plan to choose again evaluation may behave in the main responsibility of the ability, the rights of competence, responsibility ability feasibility study. According to the existing laws and regulations on drug evaluation responsibility subject localization again analysis, judge its feasibility, or need to consummate content. With foreign drugs again evaluation system for main responsibility orientation as reference, according to the requirements of the "drugadministration law, from the actual situation in our country, the paper points out the liability subject classification should be induces the main responsibility of rights and obligations. Finally, to our country already listed drug again evaluation responsibility subjects are proposed. Results and conclusion: because already listed drug again evaluation is a systematic project, so drug production, circulation, use, supervision and management involved production, trading enterprises and medical organizations, government agencies, etc. Are all should shoulder the drugs listed again after the evaluation work. Still can establish third-party evaluation institutions involved in complete already listed drug again evaluation.